Pharmaceutical Omega-3 API Market Expected to Reach USD 2.3 Billion by 2036 Driven by Prescription Cardiovascular Therapies

The global pharmaceutical omega-3 active pharmaceutical ingredient (API) market is poised for substantial growth, with projections indicating a rise from USD 1.1 billion in 2026 to USD 2.3 billion by 2036, registering a compound annual growth rate (CAGR) of 7.7% during the forecast period. This expansion is driven by rising prescription demand for cardiovascular-risk reduction therapies and increasing reliance on pharmaceutical-grade marine lipid purification, as reported by Future Market Insights (FMI).

Unlike consumer omega-3 supplements, pharmaceutical omega-3 APIs are valued for their clinical efficacy in managing severe hypertriglyceridemia and residual cardiovascular risk. Market growth is fueled by the continued adoption of icosapent ethyl, increased use of prescription EPA-based therapies, and tighter regulatory expectations surrounding API purity, documentation, and supply continuity. The industry is witnessing a shift from commodity marine oils to highly purified, dossier-backed APIs supported by Drug Master Files (DMF) and Certificates of Suitability (CEP). This transition reflects growing buyer preference for suppliers capable of meeting global regulatory requirements while ensuring batch consistency and softgel formulation performance.

Marine fish oil remains the dominant feedstock, while ethyl ester concentrates continue to lead product form demand, accounting for 64.2% of total market share in 2026. As reimbursement pressures and generic competition intensify, API manufacturers with strong purification capabilities, regulatory depth, and resilient marine supply chains are expected to capture long-term market leadership.

Icosapent ethyl dominates the API landscape and is expected to capture 41.6% market share in 2026, driven by strong prescription adoption in cardiovascular-risk reduction therapies. Other important API types include omega-3-acid ethyl esters 90, EPA ethyl ester concentrates, DHA ethyl ester concentrates, and mixed EPA-DHA triglyceride APIs. Single-molecule purified EPA products command premium pricing due to stronger clinical positioning versus mixed omega-3 formulations.

Regulatory readiness is a key growth engine, with DMF and CEP-supported APIs projected to account for 58.4% of the market in 2026. This regulatory filing support has become a competitive differentiator as pharmaceutical manufacturers prioritize suppliers with documentation accepted across major regulated markets. The United States remains the largest and most strategically important market, projected to reach USD 726.4 million by 2036, growing at 7.5% CAGR. Saudi Arabia is the fastest-growing country, expected to expand at 9.2% CAGR through 2036, reaching USD 63.8 million, driven by specialty cardiovascular care expansion and efficient regulatory review under SFDA.

Competition is intensifying among pharmaceutical API producers, marine purification specialists, and contract manufacturers. Leading participants include KD Pharma, BASF Pharma Solutions, and Croda International, all of which compete on purification capabilities and regulatory dossier strength. Amarin Corporation remains highly influential through prescription EPA therapy demand linked to VASCEPA and VAZKEPA commercialization. Regional players such as Catalent, Apotex, and Hanmi Pharmaceutical continue expanding manufacturing and commercialization capabilities.

Investment is shifting toward suppliers with vertically integrated marine sourcing and advanced purification assets. Strategic partnerships between API manufacturers, softgel converters, and finished-dose sponsors are becoming increasingly important. Long-term supply agreements are being used to secure capacity amid rising demand for purified EPA products. Licensing agreements are also expanding geographic reach, with commercial rollouts across Europe, North America, and Asia increasing repeat API procurement volumes.

Future growth will be shaped by expansion of prescription EPA therapies, stronger cardiovascular prevention strategies, improved purification technologies, rising regulatory scrutiny, and broader reimbursement coverage. The industry is likely to see continued movement toward higher-purity APIs with superior documentation and stronger softgel performance validation. For more detailed insights, the complete report is available in PDF format at Future Market Insights.